KRAS G12V MUTANT ADVANCED EPITHELIAL CANCERS

Clinical trials for KRAS G12V MUTANT ADVANCED EPITHELIAL CANCERS explained in plain language.

Never miss a new study

Get alerted when new KRAS G12V MUTANT ADVANCED EPITHELIAL CANCERS trials appear

Sign up with your email to follow new studies for KRAS G12V MUTANT ADVANCED EPITHELIAL CANCERS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Engineered immune cells target deadly cancer mutation

Disease control TEMPORARILY_NOT_AVAILABLE

This trial is testing a personalized cell therapy for people with advanced cancers that have a specific genetic change called KRAS G12V. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack the cancer, and then infuse them back into the p…

Matched conditions: KRAS G12V MUTANT ADVANCED EPITHELIAL CANCERS

Sponsor: Providence Health & Services • Aim: Disease control

Last updated Mar 30, 2026 14:33 UTC

KRAS G12V MUTANT ADVANCED EPITHELIAL CANCERS

Get alerted when new KRAS G12V MUTANT ADVANCED EPITHELIAL CANCERS trials appear

Engineered immune cells target deadly cancer mutation